HK1146242A1 - Use of melanocortins to treat insulin sensitivity - Google Patents

Use of melanocortins to treat insulin sensitivity

Info

Publication number
HK1146242A1
HK1146242A1 HK11100510.8A HK11100510A HK1146242A1 HK 1146242 A1 HK1146242 A1 HK 1146242A1 HK 11100510 A HK11100510 A HK 11100510A HK 1146242 A1 HK1146242 A1 HK 1146242A1
Authority
HK
Hong Kong
Prior art keywords
melanocortins
insulin sensitivity
treat insulin
treat
sensitivity
Prior art date
Application number
HK11100510.8A
Other languages
English (en)
Chinese (zh)
Inventor
Heather A Halem
Michael Dewitt Culler
Andrew A Butler
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of HK1146242A1 publication Critical patent/HK1146242A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK11100510.8A 2007-11-05 2011-01-19 Use of melanocortins to treat insulin sensitivity HK1146242A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US193307P 2007-11-05 2007-11-05
PCT/US2008/012490 WO2009061411A2 (fr) 2007-11-05 2008-11-05 Utilisation de mélanocortines pour traiter une sensibilité à l'insuline

Publications (1)

Publication Number Publication Date
HK1146242A1 true HK1146242A1 (en) 2011-05-27

Family

ID=40626385

Family Applications (3)

Application Number Title Priority Date Filing Date
HK11100510.8A HK1146242A1 (en) 2007-11-05 2011-01-19 Use of melanocortins to treat insulin sensitivity
HK13112170.2A HK1184692A1 (zh) 2007-11-05 2013-10-29 黑皮質素治療胰島素敏感的應用
HK16109223.2A HK1221147A1 (zh) 2007-11-05 2016-08-02 使用黑素皮質素治療胰島素敏感性

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK13112170.2A HK1184692A1 (zh) 2007-11-05 2013-10-29 黑皮質素治療胰島素敏感的應用
HK16109223.2A HK1221147A1 (zh) 2007-11-05 2016-08-02 使用黑素皮質素治療胰島素敏感性

Country Status (21)

Country Link
US (6) US9155777B2 (fr)
EP (2) EP2979703B1 (fr)
JP (3) JP2011502987A (fr)
KR (3) KR20150013339A (fr)
CN (2) CN103316345B (fr)
AR (1) AR069461A1 (fr)
AU (1) AU2008325194B2 (fr)
BR (1) BRPI0819188B1 (fr)
CA (2) CA2704651C (fr)
DK (1) DK2214693T3 (fr)
ES (2) ES2690556T3 (fr)
HK (3) HK1146242A1 (fr)
HU (1) HUE026842T2 (fr)
IL (2) IL205554A (fr)
NZ (1) NZ585131A (fr)
PL (1) PL2214693T3 (fr)
PT (2) PT2979703T (fr)
RU (1) RU2453328C2 (fr)
TR (1) TR201815292T4 (fr)
TW (1) TWI374030B (fr)
WO (1) WO2009061411A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2450017C2 (ru) * 2007-05-25 2012-05-10 Ипсен Фарма С.А.С. Лиганды меланокортиновых рецепторов, модифицированные гидантоином
TR201815292T4 (tr) * 2007-11-05 2018-11-21 Board Of Supervisors Of Louisiana State Univ And Agriculture And Mechanical College İnsüli̇n duyarliliğinin tedavi̇si̇nde melanokorti̇nleri̇n kullanimi.
CN102458436B (zh) 2009-06-08 2015-06-03 帕拉丁科技公司 黑皮质素受体特异性肽
WO2010144341A2 (fr) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Peptides spécifiques des récepteurs aux mélanocortines à pont lactame
CN102548399A (zh) * 2009-08-05 2012-07-04 益普生制药股份有限公司 黑皮质素治疗血脂异常的用途
DK2473518T3 (en) 2009-08-31 2017-03-27 Tensive Controls Inc Stabilized melanocortin ligands
RU2548753C2 (ru) * 2009-11-16 2015-04-20 Ипсен Фарма С.А.С. Фармацевтические композиции лигандов рецепторов меланокортинов
CA2781402C (fr) 2009-11-23 2017-03-21 Palatin Technologies, Inc. Peptides cycliques specifiques du recepteur de la melanocortine-1
KR20120102716A (ko) 2009-11-23 2012-09-18 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴-1 수용체 특이적 선형 펩티드
MX341642B (es) * 2011-06-14 2016-08-29 Ipsen Pharma Sas Composicion de liberacion sostenida que contiene peptidos como ingredientes activos.
HUE056948T2 (hu) 2011-12-29 2022-04-28 Rhythm Pharmaceuticals Inc Melanokortin-4 receptorral összefüggõ rendellenességek kezelési módszere heterozigóta hordozókban
US9534018B2 (en) 2012-03-13 2017-01-03 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
CN105518021A (zh) 2013-03-15 2016-04-20 节奏制药公司 药物组合物
EP3450449A3 (fr) 2013-03-15 2019-06-12 Rhythm Pharmaceuticals, Inc. Compositions peptidiques
US10314883B2 (en) 2015-02-13 2019-06-11 University Of Virginia Patent Foundation Compositions and methods for regulating blood pressure
WO2017019952A1 (fr) 2015-07-29 2017-02-02 University Of Virginia Patent Foundation Compositions et procédés de régulation de l'adhésion des leucocytes
EP3350200A4 (fr) 2015-09-18 2019-03-27 Wake Forest University Health Services Analogues d'angiotensine (1-7) et procédés associés
US11124541B2 (en) * 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
US11763106B2 (en) 2018-06-05 2023-09-19 The Research Foundation For The State University Of New York Method for passive wireless channel estimation in radio frequency network and apparatus for same
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
EP1322954A4 (fr) * 2000-09-13 2005-08-03 Eleanor Roosevelt Inst Procede de traitement de la resistance a l'insuline dans l'obesite et le diabete
WO2003099818A1 (fr) * 2002-05-23 2003-12-04 Chiron Corporation Composes de quinazolinone substitues
DE60313844T2 (de) * 2003-03-20 2008-01-31 Santhera Pharmaceuticals (Schweiz) Ag Substituierte Piperidin- und Piperazin-Derivative als Melanocortin-4 Receptor Modulatoren
DE602004028228D1 (de) 2003-03-26 2010-09-02 Merck Sharp & Dohme Bicyclische piperidin-derivate als melanocortin-4 rezeptor-agonisten
BRPI0409976A (pt) 2003-05-09 2006-05-09 Novo Nordisk As composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto
CN1784423A (zh) * 2003-05-09 2006-06-07 诺沃挪第克公司 用于治疗肥胖的肽
KR20060026011A (ko) * 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
JP2006527773A (ja) * 2003-06-19 2006-12-07 イーライ リリー アンド カンパニー メラノコルチン受容体４（ｍｃ４）作用薬とその用途
EP1732586A1 (fr) 2004-03-29 2006-12-20 Eli Lilly And Company Utilisations de peptides agonistes du recepteur de la melanocortine 4 (mc4r) administres par perfusion continue
US20080200376A1 (en) * 2004-10-29 2008-08-21 Maccoss Malcolm Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction
KR20080041639A (ko) 2005-07-08 2008-05-13 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. 멜라노코르틴 수용체의 리간드
PL2286825T3 (pl) 2005-07-08 2017-06-30 Ipsen Pharma Ligandy receptora melanokortyny
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
RU2450017C2 (ru) 2007-05-25 2012-05-10 Ипсен Фарма С.А.С. Лиганды меланокортиновых рецепторов, модифицированные гидантоином
TW200848424A (en) 2007-06-15 2008-12-16 Sod Conseils Rech Applic Cyclic peptide melanocortin receptor ligands
TR201815292T4 (tr) * 2007-11-05 2018-11-21 Board Of Supervisors Of Louisiana State Univ And Agriculture And Mechanical College İnsüli̇n duyarliliğinin tedavi̇si̇nde melanokorti̇nleri̇n kullanimi.
CN102548399A (zh) 2009-08-05 2012-07-04 益普生制药股份有限公司 黑皮质素治疗血脂异常的用途

Also Published As

Publication number Publication date
EP2214693A4 (fr) 2012-04-11
CA2704651C (fr) 2017-03-07
TW200932258A (en) 2009-08-01
TWI374030B (en) 2012-10-11
ES2690556T3 (es) 2018-11-21
US9827286B2 (en) 2017-11-28
KR20130065725A (ko) 2013-06-19
KR20150013339A (ko) 2015-02-04
CN103316345A (zh) 2013-09-25
DK2214693T3 (en) 2015-11-30
CN103316345B (zh) 2016-05-18
CA2952095C (fr) 2020-02-18
KR101662044B1 (ko) 2016-10-04
KR20100075680A (ko) 2010-07-02
NZ585131A (en) 2012-10-26
ES2555522T3 (es) 2016-01-04
EP2214693B1 (fr) 2015-09-09
PT2214693E (pt) 2015-12-07
EP2979703B1 (fr) 2018-07-18
RU2010122897A (ru) 2011-12-20
US20190111105A1 (en) 2019-04-18
JP2013144690A (ja) 2013-07-25
US20160354429A1 (en) 2016-12-08
IL205554A0 (en) 2010-12-30
IL205554A (en) 2017-01-31
CA2952095A1 (fr) 2009-05-14
IL249998B (en) 2018-07-31
JP5964767B2 (ja) 2016-08-03
EP2214693A2 (fr) 2010-08-11
JP2011502987A (ja) 2011-01-27
US20150366934A1 (en) 2015-12-24
US20100311647A1 (en) 2010-12-09
HK1221147A1 (zh) 2017-05-26
AR069461A1 (es) 2010-01-27
AU2008325194A1 (en) 2009-05-14
EP2979703A1 (fr) 2016-02-03
BRPI0819188A2 (pt) 2015-09-01
PL2214693T3 (pl) 2016-03-31
WO2009061411A2 (fr) 2009-05-14
WO2009061411A3 (fr) 2010-04-15
TR201815292T4 (tr) 2018-11-21
HUE026842T2 (en) 2016-08-29
CN101980717A (zh) 2011-02-23
IL249998A0 (en) 2017-03-30
CA2704651A1 (fr) 2009-05-14
AU2008325194B2 (en) 2012-04-19
US9155777B2 (en) 2015-10-13
RU2453328C2 (ru) 2012-06-20
JP2015131827A (ja) 2015-07-23
US20180303899A1 (en) 2018-10-25
US9439943B2 (en) 2016-09-13
US20220339239A1 (en) 2022-10-27
HK1184692A1 (zh) 2014-01-30
KR101290623B1 (ko) 2013-08-07
BRPI0819188B1 (pt) 2021-06-22
PT2979703T (pt) 2018-10-31

Similar Documents

Publication Publication Date Title
HK1221147A1 (zh) 使用黑素皮質素治療胰島素敏感性
IL213596A0 (en) Heterocyclic compounds and methods of use
HK1172896A1 (zh) 化合物和使用方法
HK1161094A1 (en) Compounds and methods of use
HK1154054A1 (en) Predictors of patient response to treatment with egf receptor inhibitors
IL208354A0 (en) Methods of treatment
GB0707750D0 (en) Treatment of organic matter
HK1160925A1 (zh) 組織蛋白酶 的用途
PL2148676T3 (pl) Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
ZA200901452B (en) Treatment of vertigo with acetyl-L-leucine
GB2448592B (en) Improvements to coffins
EP2470020A4 (fr) Composés de benzodiazépinone et méthodes de traitement les utilisant
GB0723100D0 (en) Treatment of HFnEF
EP2066171A4 (fr) Administration d'une substance de traitement à des éléments poreux
HK1156250A1 (en) Unit dosage of apadenoson
GB0814296D0 (en) Improvements to coffins
GB0802903D0 (en) Treatment of diabetes
GB0801958D0 (en) Improvements relating to electro-optical sensors and their use
IL190834A0 (en) Improvements to bandages
GB0816217D0 (en) Treatment of hepatitis C
HU0800656D0 (en) Effective use of tea-composition
GB0809469D0 (en) Improvements relating to body jewelry
FI20080503A0 (fi) MSM-elementtien pintakäsittely
GB0717139D0 (en) Treatment of hepatitis C
GB0719334D0 (en) Improvements relating to electro-optical sensors and their use